Dear Editor,
CRISPR/Cas systems are widespread RNA-mediated prokaryotic adaptive immune systems providing protection against invading nucleic acids [1] . However, throughout evolution, this host defense system has not resulted in the eradication of phages, suggesting that phages have evolved counter strategies to thrive within bacteria despite these mechanisms [2] . Thus, both bacterial CRISPR system and phage anti-CRISPR system are part of a continuing evolutionary battle between bacterial host and their bacteriophage invaders.
The fight against phages through CRISPR/Cas systems occurs in three stages. For example, for the type I-F CRISPR/Cas system, Cas1 and Cas2 proteins first insert a short segment 'spacer' derived from the foreign DNAs into the CRISPR locus. Subsequently, the CRISPR array is transcribed into a long precursor crRNA, which is further processed into the mature crRNA by Csy4 protein.
Finally, this stable Csy4-crRNA complex subsequently assembles with Csy1, Cys2 and Csy3 protein, forming a crRNA-guided surveillance complex (named Csy complex) ( Figure 1A ). The Csy complex specifically recognizes the complementary target DNA and recruits Cas3 to degrade the invading DNA [3] .
To proliferate inside their bacterial hosts, phages must overcome bacterial defense mechanisms, such as the CRISPR/Cas immune system. It was shown earlier that within a population, certain phages display a mutation in the protospacer or in the protospacer adjacent motif (PAM), thus evading CRISPR targeting. Recently, an alternative approach for evading CRISPR/Cas activity, which lacks a requirement for mutation in the protospacer or PAM region [4] , was described for Pseudomonas aeruginosa. The anti-CRISPR prophages contain a set of atypical genes encoding five small phage proteins involved in inactivating the CRISPR/Cas system. Subsequently, another study characterized three of these anti-CRISPR proteins (AcrF) [5] . AcrF1 and AcrF2 directly bind to the Csy complex, thus blocking target DNA binding. In comparison, AcrF3 interacts directly with the Cas3 protein and blocks its recruitment into Csy complex, thus protects the phage DNA from being degraded by the CRISPR/Cas system.
While previous studies have provided crucial first insights into the molecular mechanisms of anti-CRIS-PR activities, it remains to be elucidated as to how the AcrF3 inhibits crRNA interference. To find answers to this question, we set out to solve the crystal structure of AcrF3 and the cryo-electron microscopy (cryo-EM) structure of AcrF3-Cas3 complex. Our structural analysis provides important insights into how the AcrF3 dimer binds Cas3 protein at the entrance of non-complementary strand into Cas3. As a result, recruitment of Cas3 by the Csy complex is inhibited, thus effectively preventing the degradation of phage DNA by the CRISPR/Cas system.
To reveal the molecular details of how AcrF3 inhibits CRISPR/Cas activity, we performed crystal structure analysis of the cloned and purified AcrF3 protein encoded by gene 35 from phage JBD5. The structure of the seleno-methionine substituted AcrF3 was solved to 1.5 Å resolution (Supplementary information, Table S1 ). As shown in Figure 1B , the AcrF3 is a dimer, with each monomer comprising six α-helices. Dimer formation is facilitated by the interaction between the first α-helices of two AcrF3 subunits ( Figure 1B) .
To understand how the AcrF3 protein interacts with type I-F P. aeruginosa Cas3 ( Figure 1C ), we prepared the PaeCas3-AcrF3 complex (Supplementary information, Figure S1A and S1B), and solved the cryo-EM structure of PaeCas3-AcrF3 complex at resolution of 4.2 Å using cryo-EM single particle method ( Figure 1D ). In the 4.2 Å density map, the secondary structures such as α-helix and β-strand were resolved (Supplementary information, Figure S1C -S1F). A model of PaeCas3 was built based on the electron density map and the crystal structure of AcrF3 dimer fits well to the density of the rest of the map. However, due to the flexibility, certain loops were not resolved and remained unidentified in the map.
Similar to Thermobifida fusca Cas3 (TfuCas3) [6] and Thermobaculum terrenum Cas3 (TteCas3) [7] , PaeCas3 also contains five conserved domains: HD, Rec1, Rec2, Linker and CTD, and the helicase domain forms a cleft to accommodate single-stranded DNA ( Figure 1E ). In order to analyze the conformational change of Cas3 induced by AcrF3 binding, we performed a structural comparison of PaeCas3, TfuCas3 and TteCas3. As shown in Supplementary information, Figure S1G , the structures of the Rec1 and Rec2 domains are well conserved, despite their low sequence similarity. The topology of Rec1 and Rec2 are nearly identical for PaeCas3, TfuCas3 and Tte-Cas3, except for the presence of two additional α helices in TfuCas3 and TteCas3. In contrast, the HD and CTD domains exhibit significant differences among PaeCas3, TfuCas3 and TteCas3.
As shown in Figure 1D , the AcrF3 is present as a dimer in the Cas3-AcrF3 complex. One AcrF3 monomer interacts with the HD and Linker of Cas3 protein, and the other monomer interacts with the CTD domain ( Figure  1F ). Thus, AcrF3 dimer connects the HD and CTD domains of Cas3, and covers the cleft formed inside Cas3 protein ( Figure 1G ). The Cas3 protein is recruited by the Csy complex following pairing of the crRNA bases with those of the complementary strand, generating an R-loop conformation with a displaced non-complementary strand. Interestingly, the AcrF3 dimer binding site of Cas3 is the entrance of the displaced single-stranded DNA associated with Cas3, suggesting that the AcrF3 dimer blocks the access to Cas3 of the non-target DNA ( Figure 1H ). Without Cas3 recruitment by the Csy-dsD-NA complex, the CRISPR/Cas system is unable to efficiently destroy the invading phage DNA, resulting in the escape of phages from the immune response.
As shown in Figure 1F the loop between α6 and α7, and the loop between α5 and α6 of HD domain interact with one AcrF3. In the PaeCas3 CTD domain, the loop between α36 and β22, and the loop between β19 and β20 interact with the other AcrF3 monomer. In order to investigate whether AcrF3 is able to bind other Cas3, we aligned the PaeCas3, TfuCas3 and TteCas3 protein sequences. As shown in Supplementary information, Figure S1H , the Rec1 and Rec2 sequences are conserved, whereas the regions of Cas3 interacting with AcrF3 (highlighted by a blue box in Supplementary informa-tion, Figure S1H ) are not conserved, suggesting that AcrF3 cannot bind TfuCas3 and TteCas3 proteins. This is in agreement with earlier result showing that the AcrF3 protein is highly specific for the Pseudomonas I-F CRIS-PR system [4] .
Cas3 plays critical roles during the process of primed spacer acquisition. When crRNA interference is unsuccessful due to the phage mutation, some infected bacterial host cells survive by acquiring new spacer sequences directly from the invading phage genome [8] . In addition to Cas1 and Cas2, Csy complex and the Cas3 nuclease are involved during the primed acquisition. Recently, it was found that the Cas1-Cas2 complex associates with the Cas3 protein during primed acquisition [9] . The degradation products of Cas3 are used by Cas1-Cas2 as precursors for new spacers.
In the type I-F CRISPR system, Cas2 and Cas3 are coded by one gene as a fused protein, with Cas2 located at the N-terminal of Cas3. During the preparation of our manuscript, a similar crystal structure of AcrF3 bound with Cas3 complex was published [10] (Supplementary information, Figure S1I ). While Cas2 was clearly observed in this reported AcrF3-Cas3 structure, Cas2 is disordered in our cryo-EM complex structure due to the flexibility of this region. To reveal whether the presence of AcrF3 protein affects spacer acquisition and to gain knowledge of the Cas1-Cas2-Cas3 complex, we made the model of Cas1-Cas2-Cas3 complex ( Figure 1I ) by superposing the Cas2 from structure 5B7I and the Cas2 protein in the Cas1-Cas2 complex [11] . The Cas1-Cas2-Cas3 complex contains two Cas1 dimers, one Cas2 dimer and two Cas3 proteins, with Cas2 dimer sandwiched by two Cas1 dimers and two Cas3 proteins from orthogonal direction. Cas3 associates with Cas1-Cas2 complex by the interaction between its Rec1 domain and Cas2. The AcrF3 dimer binding surface is located on the opposite site of Cas2, suggesting that AcrF3 has little effect on the assembly of the Cas1-Cas2-Cas3 complex. Thus is unlikely to interfere with primed acquisition directly. However, AcrF3 inhibits Cas3 recruitment by Csy-dsD-NA complex, thus stopping the generation of the precursor protospacer DNA. As a result, phage AcrF3 protein blocks both crRNA interference and spacer acquisition.
In conclusion, our structural analysis of the Cas3-AcrF3 complex revealed that the AcrF3 dimer binds to HD, Linker and CTD domains of the Cas3 protein, therefore blocking the replaced non-complementary DNA access of Cas3. Therefore, AcrF3 inhibits crRNA-mediated DNA degradation via inhibiting recruitment of Cas3 by Csy complex. In addition, inhibition of Cas3-guided DNA degradation also blocks primed spacer acquisition. In summary, the AcrF3 dimer overcomes the CRISPR system at both the crRNA interference and the primed acquisition stages. Our studies provide new insights into the ongoing molecular arms race between viral parasites and the immune systems of their hosts. 
